UK HTA Body To Conduct More Appraisals, And Faster, Through Proportionate Approach
Executive Summary
Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.
You may also be interested in...
UK Blood Cancer Patient Group Wants More Price Flexibility
An alliance of blood cancer charities has called for multi-indication and combination pricing to be introduced in the UK as part of a future pricing and access deal. The group also requested a transparent and formal way of involving patients as the government and industry negotiate a successor to the Voluntary Scheme for Branded Medicines Pricing and Access, which is due to end in 2023.
UK: Will Companies Remaining In Voluntary Payment Scheme End Up With A Bigger Bill?
Uncertainty over the payments that will be due from companies to manage the branded medicines bill in 2023 and beyond has been a cause for concern for firms, which last month had to decide whether to remain in or exit the Voluntary Scheme for Branded Medicines Pricing and Access. If many companies have left, the “remainers” might end up paying more than their fair share, though the government has offered some assurance on this front.
Economic Crisis Expected To Shape UK’s Future Drug Pricing Deal
The pharmaceutical industry has warned the UK’s new government about the impact of unprecedented industry payments on medicines supply in the short term and their potential to reduce inward investment in the long term. Along with economic pressures, these considerations will be among the factors forming the backdrop to negotiations on a deal that will determine pricing and access for branded medicines from 2024 onwards.